Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study-

Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study- - Oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study-

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024397

Enrollment

Registered

2016-12-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

food allergy

Interventions

To examine the efficacy and safety for months 18 at the start of the randomized study of oral immunotherapy combination with omalizumab for severe cow&#39

s milk allergy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Children who gain desensitization of cow's milk after the randomized study of oral immunotherapy for severe cow's milk allergy and who continue daily cow's milk ingestion. 2. Children who obtain the informed consent of the study

Exclusion criteria

Exclusion criteria: 1. Children who have acute disease and chronic disease except allergic disease. 2.Children or guardian who deny the study 3. Children who were judged as inappropriate by the study director

Design outcomes

Primary

Measure	Time frame
The percentages of sustained unresponsiveness at the months 18 after the start of the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy	—

Secondary

Measure	Time frame
The frequencies of allergic reactions from the start to the months 18 after the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy	—

Countries

Japan

Contacts

Public ContactShoichiro Taniuchi

Kansai Medical University Department of Pediatrics

taniuchi@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow&#39;s milk allergy- follow up study-